WO1994018906A1

WO1994018906A1 - Implantable artificial organ

Info

Publication number: WO1994018906A1
Application number: PCT/US1994/001734
Authority: WO
Inventors: Anthony P. Monaco; Takashi Maki; Jeremy Peter Alan Lodge
Original assignee: New England Deaconess Hospital, Corp.
Priority date: 1993-02-18
Filing date: 1994-02-18
Publication date: 1994-09-01
Also published as: AU6243294A

Abstract

Implantable artificial organs are disclosed for delivery of a biological agent from implanted cells placed within the body cavity of a subject. The cells (32) are maintained within a selectively permeable membrane (22), which permits the movement of the agent therethrough while excluding white blood cells (immunocytes), antibodies and other detrimental agents present in the environment of use from gaining access to the cells. The selectively permeable membrane is completely enclosed by a perforated housing (12) which protects the membrane from breakage and permits body fluids to be in close contact with the membrane. Implantable artificial organs are disclosed, all of which may be retrieved from the subject, replaced or recharged and reimplanted.

Description

IMPLANTABLE ARTIFICIAL ORGAN

BACKGROUND OF THE INVENTION

Semipermeable membranes containing a cell which produces a biologically active substance often are implanted into a subject's body for a variety of purposes. The membrane allows bodily fluids to diffuse in and out of the membrane but prevents the movement of the subject's immune cells into the membrane. As a result, implantable semipermeable membranes have been used to immunoisolate parasitic cell or infective larvae in studies relating to the immune response of a host to parasitic infection. Diffusion housings have also been used to study in vivo or in vitro bacterial pathogenesis, e.g., Bordetella pertussis pathogenesis.

Much research has been focused on the use of semipermeable diffusion membranes for treatment of diabetes. Using such methods, pancreatic islet cells are enclosed in a semipermeable diffusion membrane which is then implanted in a diabetic mammal. Insulin diffuses through the diffusion membrane and can ameliorate diabetic conditions for limited periods of time. Nutrients diffuse through the membrane to support metabolism of islet cells.

Implantable, semipermeable diffusion membranes have a number of disadvantages. Most significantly. implantation of numerous semipermeable membranes such as beads, straws, or discs into a body cavity of a patient in large numbers makes retrieval extremely difficult, if not impossible. In the case of cells with a limited life span, re-implantation of the individual membranes containing fresh cells is very difficult, time-consuming and dangerous to the patient, especially if the membranes become scattered throughout the body cavity by movement of the patient. Furthermore, diffusion membranes are subject to breakage during, and after, the implantation process and during subsequent activity of the patient. Breakage of the membranes can lead to spillage of the enclosed cells, thus exposing the cells to the patient's immune system. Rejection of the cells and non-specific inflammatory reactions often result, and this can cause significant morbidity in patients, particularly if such membranes are placed in the peritoneal cavity. Also, use of an agent, such as epoxy to seal the ends, sides, or circumference of the semipermeable diffusion membranes is problematic since the epoxy may volatilize within the body and release unwanted organic chemicals that are possibly toxic to the implanted cells.

It is appreciated by those of ordinary skill in the art that several hundred diffusion membranes are often needed to ameliorate diabetic conditions in dogs. Thus, implantation of several hundred individual membranes in a human poses almost insuperable problems with regard to breakage of the membranes and retrieval of the membranes.

-2-

SU8STITUTE SHEET(RULE 26) SUMMARY OF THE INVENTION

The present invention pertains to an artificial implantable organ. The artificial organ includes a first housing having at least one interior and at least one exterior surface. The interior surface(s) define a chamber and the exterior and interior surfaces are in fluid communication with each other. At least a portion of the first housing is accessible to bodily fluids. A membrane is disposed within the chamber, at least a portion of the membrane being selectively permeable to bodily fluids. The membrane contains one or more cells ("cells") capable of producing a biological agent such as a hormone, cellular growth factor, and the like. The cells are preferably disposed entirely within the confines of the membrane. Preferably, the first housing is a geometrical shape having interconnected interior surfaces and exterior surfaces. The interior and exterior surfaces in closest facing relationship to each other are perforated. In this way, the housing can be arranged to allow bodily fluids to pass transversely through the housing to completely and persistently be in contact with the semipermeable membrane. The selectively permeable membrane allows nutrients in body fluids to pass through it to nourish the contained cells and permits a biological agent produced by the cells to pass through the membrane. The membrane prevents the cells from immunological attack, rejection, or physical escape.

The selectively permeable membrane that is disposed within the chamber of the first housing can include a plurality of tubular membranes. In one embodiment of the invention, these tubular membranes are arranged within the chamber in a pinwheel configuration. In another embodiment, a plurality of tubular membranes are arranged parallel to each other within the chamber. Further configurations of the invention include a single, tubular membrane coiled within the chamber. The tubular membrane can also be coiled around a second housing that is concentrically disposed within the chamber of the first housing. Further embodiments include a cellular growth factor disposed within the membrane.

A preferred selectively permeable membrane is a tube with closed ends whose total length is substantially greater than any linear dimension of the first housing. In another preferred embodiment, the selectively permeable membrane is a closed tube disposed within the chamber of the first housing, the tube having an internal volume that is substantially equal to the internal volume of the chamber.

The implantable artificial organ is assembled and loaded with cells prior to implantation. Kits of the invention therefore include loaded and assembled artificial organs.

The invention also pertains to methods for delivering a beneficial agent to a body using the artificial organ of the invention.

It is also an object of the present invention to provide an artificial implantable organ that is easily retrievable.

It is a further object of the present invention to

-4- SU8STITUTE SHEET (KJLE 26) provide an artificial implantable organ that protects a selectively permeable membrane from breakage during the implantation process.

It is yet another object of the present invention to provide an artificial implantation organ that is easily fabricated from readily available materials.

It is another object of the present invention to provide an artificial organ containing a selectively permeable membrane, which membrane is designed to minimize its sealed edges, while maximizing the total surface area thereof.

It is a further object of the present invention to provide an artificial organ utilizing selectively permeable membranes, which organ is small enough to be implanted into the abdominal cavity with minor surgery under local anesthetic or laparaεcopic techniques.

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. l is a schematic, cross-section illustration of the implantable artificial organ of the present invention;

Fig. 2 is a schematic, top-view illustration of another embodiment of the implantable artificial organ of the invention;

Fig. 3 is a cross-sectional view through line A-A of the embodiment of Fig. 2.

Fig. 4 is a schematic, top view illustration of another embodiment of the implantable artificial organ of the invention;

Fig. 5 is a cross-sectional view through line B-B of the embodiment of Fig. 4.

-5- SU8STITUTE SHEET(RULE 26) Fig. 6 is an alternate embodiment of Figs. 4 and 5 5 in cross-εecticn.

Fig. 7 is a schematic, top view illustration of another embodiment of the implantable artificial organ of the invention;

Fig. 8 is a partial cut-away view of another embodiment of the implantable artificial organ of the invention.

Fig. 9 is a partial cross-sectional view through line C-C of Fig. 8.

Fig. 10 is a partial cross-sectional view of an alternate embodiment of Figs. 8 and 9.

Fig. 11 is a schematic, cross-sectional illustration of another embodiment of the implantable artificial organ of the invention.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to an artificial organ for implantation into a subject, and processes for implanting and using such organs within the body of the subject. The term "subject" in this context refers primarily to humans, although non-human vertebrates such as primates, dogs, cats, horses and the like are also included within the meaning of the term.

Various characteristics of the implantable artificial organ are controlled so that the organ has the capability of preventing entry of immunologically active substances (i.e. lymphocytes, macrophageε, circulating antibodies, and the like) into the artificial organ, thus simultaneously housing biologically active cells in the organ and protecting the cells from the immunologically active substances. At the same time, the artificial organ permits the ingress of nutrients and body fluids therein and permits the egress of waste products and biological agents produced by the biologically active cell from the artificial organ. The result is a viable, ongoing source of a biological agent contained within the artificial organ which functions on a relatively long-term basis without rejection (immunological destruction) by the subject.

Fig. 1 illustrates in schematic form a cross-sectional view of the general construction and operation of the present implantable artificial organ. The artificial organ 10 includes a first, three-dimensional housing 12 having at least one exterior surface 14 and at least one interior surface 16. In Fig. 1, the first housing 12 is a hollow sphere with one interior and exterior surface. The interior surface 16 of the first housing 12 defines a chamber 18. At least a portion of the first housing's exterior 14 and interior 16 surfaces contain perforations 20 that render at least that portion of the first housing accessible to bodily fluids. A membrane 22 is disposed within chamber 18. Membrane 22 includes interior 24 and exterior 26 surfaces. A portion 28 of these surfaces 24,26 is selectively permeable to bodily fluids. The interior surface 24 of membrane 22 defines an internal volume 30, hereinafter referred to as a lumen. One or more biologically active cells 32 (hereinafter "cells") capable of producing a biological agent are disposed completely within lumen 30 of membrane 22. The interior surface 16 of first housing 12 and exterior surface 26 of membrane 22 define between them a volume 34 that is accessible to bodily fluids. In Fig. 1., volume 34 is also free of the biologically active cells 32.

First housing 12 can be compatible with implantation into a living body and can be of sufficient thickness and of sufficient inflexibility to protect membrane 22 from breakage. The first housing 12 can be comprised of, for example, stainless steel, titanium, or other implantable substances, including organic polymers such as a variety of plastics, so long as the material is non-reactive (i.e. biologically inert). For example, the first housing can be polytetrafluoroethylene, silicon-coated plastic, polycarbonate, polysulfone, polymethyl methacrylate or mixtures thereof. The first housing can also be fabricated of woven or fibrous materials, such as, for example Dacron or polytetrafluoroethylene mesh.

As mentioned above, at least part of the first housing 12 is accessible to bodily fluids. The term "accessible" refers to a characteristic of at least part of the first housing 12 that allows bodily fluids to be in fluid communication with the housing without any restrictions or molecular size exclusions. The term "accessible" particularly refers to fluid communication that relies on passive movement of bodily fluids and is not meant to include fluid communication based upon connection of the artificial organ to blood vessels and/or lymph ducts for active pumping of fluids through the artificial organ. "Bodily fluids" means plasma, blood, lymph, urine, salts, gases, metabolic products, solutes, cell cytoplasm, and other liquid and gaseous materials found within the body of a subject.

Accessibility to bodily fluids of the first housing 12 is effected by the presence of a plurality of perforations 20 that will allow the passive entrance and exit of bodily fluids. The perforations can include a variety of shapes and configurations. The perforations can be of any size, so long as the membrane 22 is protected from physical damage by adjacent body organs or cells.

In one embodiment (illustrated in Fig. 1), the first housing 12 has a plurality of perforations 20 of substantially circular cross section, each perforation consisting essentially of a thin tube extending from exterior surface 14 to the interior surface 16 of the first housing 12. In other embodiments, the perforations may include an interconnected matrix of substantially tubular pores. For example, if the first housing 12 is made of a woven material such as Dacron, or other similar polymer, the perforations 20 of first housing 12 are configured in a grid or mesh work configuration and include a lattice of overlapping and/or interconnected mesh.

Referring again to Fig. 1, the housing 12 completely encloses membrane 22. A "membrane" is a thin sheet or layer. At least a part of the membrane is selectively permeable. The term "selectively permeable" refers to membranes characterized in their ability to permit entry only of a certain kind and

-9-

SUBSTITUTb SHEET (RULE 26) size of material. A selectively permeable membrane 22 should bar components of the cell-mediated and humoral immunological responses, i.e., macrophages, complement, lymphocytes and antibodies from entry into the membrane while allowing the passage of bodily fluids (i.e. salts, blood plasma, blood, lymph, growth factors, nutrients, gases, metabolic breakdown products, solutes) and the biological agent produced by the cells to pass therethrough. Thus, in this manner, bodily fluids can pass into the membrane 22 and interact with the cells contained within the membrane. Any biological agent(s) released by the cells will exit membrane 22, pass through chamber 18, out of the housing 12 and be released into the body. Thus, the properties of the selectively permeable membrane allow it to act as a physical barrier to retain the cells within it while allowing non-cellular materials and products to pass unhindered, and to prevent antibodies and immune cells of a host from penetrating into the lumen of the membrane and destroying the cells. So long as these requirements are met and satisfied, neither the chemical composition of the selectively permeable membrane, nor the perforation size of the membrane is of any consequence. Although Fig. 1 illustrates a three-dimensional membrane 22 completely enclosing cells 32, it will be understood that membrane 22 can also contain cells 32 that are embedded or otherwise impregnated into the membrane material itself. For example, cells 32 can be supported on the interior surface 24; and/or between interior and exterior 26 surfaces. The permeability of the membrane is a function of the composition of the particular materials used. Generally, any biologically inert material (i.e. incapable of initiating a biological reaction, such as an immune response, in the recipient subject) having perforations (referred to in this context as "pores") enabling passage of molecules with a molecular weight of between about 50,000-80,000 Daltonε is useful for the membranes of the present invention.

Well-described and commercially available selectively permeable membranes composed of various compositions are available for the membrane. These materials include εelectively permeable membranes made of acrylic resins, cellulose acetate, cellulose-nitrate, nylon, polycarbonate and other mixed eεterε. Preferably, the membrane is a porous acrylic copolymer membrane of about 50,000-80,000 Dalton average porosity such as the type XM manufactured by the Amicon Division of W.R. Grace and Company. The pore sizes of the preferred membranes are selected to provide a barrier to protect the cells from a host immune reaction. Those of ordinary skill in the art will appreciate that the appropriate pore size can be determined uεing no more than routine methods. For example, the pore size can be εelected . on the basis that the membrane must exclude greater than 90 percent of an IgG solution.

Because of thiε membrane, cells from a variety of sourceε can be implanted in a recipient subject without necessarily requiring drug-induced immune suppression of the recipient subject.

The membrane can be made in a variety of preferred

-11- shapes and forms, as illustrated in more detail below. Each of the variety of different shapeε and orientations will be constructed with a lumen volume to meet the requirements of the intended application. With embodiments of the artificial organ intended for human use, the lumen 30 of the membrane 22 can preferably range from about 0.02 to about 100 cubic centimeters and the effective distance between cells inside the membrane and the exterior surface of the first housing is preferably no greater than about 3.0 centimeters.

Generally, the membrane will be in the shape of a hollow tube or bag whose ends are sealed together uεing adheεiveε, heat, ultrasound and the like. An important feature of the present invention is that the membrane iε deεigned to minimize the area of its sealed edges relative to its total surface area. In this way, the amount of sealed surfaces in contact with the environment of use is minimized. Thiε iε particularly important if epoxy adheεiveε are used to close the ends of the membrane. The epoxy resins may volatilize and/or release undeεirable compoundε into the environment of use. Moreover, manipulation and fabrication of the present implantable organε is simplified if the membranes are made with as few sealed edges as poεεible. Preferred conεtructionε of the membrane deεigned to minimize the εealed εurface area will be preεented in more detail below.

Referring again to Fig. 1, cells 32 are contained within lumen 30 of membrane 22. Cells that are thus encapsulated and implanted may be "allografts, " or cells implanted one member of a species to another of

-12-

?^!J3STITUTE SHEET RULE 26^' the same species as the subject in which they are to be implanted, or they may be "xenografts" , or those from another of a different specieε. More particularly, they may be a component (i.e. a portion or conεtituent) of a body organ which normally εecretes a particular biological agent in vivo. The cells are desirably used as single, dispersed cells or in cell aggregate form. The actual cell size and the quantity of cells in the device of the present invention will depend to a significant degree on a correlation of various factors such as the chemical composition of the houεing, membrane configuration, the construction of the device, the cells of choice, the disease to be treated, ameliorated or controlled, the environment of use including nutrients available for generating or promoting formation of a biological agent, and other considerations.

The artificial organ will contain a quantity of cells at least sufficient to produce a biological agent that effects a desired result, and/or treats, ameliorates and/or controls a targeted disease. Illustrative examples of cells (and the biological agent(s) produced by them) include cells from the thyroid (thyroid hormone), parathyroid (parathormone) , adrenal gland (adrenalin, gluco-corticoids, steroidε), nerve cellε (nerve growth factorε), liver cellε (enzymes or coagulation proteins) . It will be appreciated that the term "cellε" can also include whole cell aggregates and can also include microorganiεms εuch aε bacteria and protozoanε, capable of producing one or more biological agentε. Moreover, genetically engineered cells and cellε modified by conjugation, hybrid DNA or fusion can be used. See, for example, Kawakami et al. Diabetes 41:956-961 (1992); Docherty, K. , "Prospects For Gene Therapy And Cellular Engineering In Diabetes,' pp. 154-182 in Biotechnology of Insulin Therapy, (ed. J.C. Pickup), Blackwell, London (1991), incorporated herein by reference. Further, cell types which can grow in suspension culture, as well aε anchorage- dependent cells can be used in this invention. Specific examples include fibroblastε, leukocyteε, ly phoblaεtoidε, pituitary cellε, and the like. The term "cells", as defined for the purposes hereof, can include cell fragments, cell clumps and single cellε. It will thuε be appreciated that the biological agent can augment activity of an organ within the body of a εubject, which organ haε loεt itε ability, or has a diminished capacity, to produce a biological agent. The proceεε and apparatus of thiε invention iε particularly suitable for using pancreatic endocrine cell from pancreatic iεletε or islet cellε for implantation into the body and for release of insulin. The optimal pancreatic islet cellε for thiε function are εubεtantially fibroblaεt-free cell preparationε derived from cultured fetal iεlet cells or intact, whole organ pancreas, which are subsequently cultured _in vitro. For purposes of clarity of explanation and not by way of limitation, the invention will be described hereinafter in terms of pancreatic islet cells, it being understood the proceεε and product iε alεo suitable for implanting other types of cellε, aε deεcribed above. Theεe other types can be considered alternates in the invention

-14- SU3STITUTE SHEET (RULE 26) description.

The concentration of islet cellε within the membrane can be from about 10 2 to 108 cells/ml.

The pancreatic iεlet cellε εuitable for incorporation into the membrane of this invention can be derived from pancreatic cell by numerous published procedures or they can be derived from cell, organ or cell cultures. The term "pancreatic islets" includes the conεtituent cell typeε within the islet of Langerhans including beta cells, the actual producers of insulin, intact islets, islet fragments, genetically engineered islet cells or combinations of the foregoing. A procedure for iεolating iεletε from a donor pancreaε iε described in Example 1.

The islet materials can also contain other cell which enhance islet viability. The presence of endothelial cellε or fibroblasts can create an environment more like that in which iεlet cells naturally occur. Other cell types which produce growth factors and/or soluble, cellular growth factorε or basement membrane components can be cultured with the isletε and included within the membrane to enhance growth and viability.

Figs. 2 and 3 illustrate one embodiment of the artificial organ of the present invention. Generally, the first housing 12 is a geometrical shape with a plurality of interconnected exterior 17 and interior 15 surfaces. In Fig. 2, the first housing 12 is a toroidal or donut configuration. It will be appreciated that a disc, square, cylinder or rectangular shape will alεo be εuitable. The toroidal first housing 12, shown in croεε-εection in Fig. 3.,

-15- SU8STITUTE SHEET(RULE 26) has two interior 15 and exterior 17 surfaces in cloεeεt facing relationship to each other. These particular surfaceε contain perforationε 20 and are acceεsible to bodily fluids. Interior surfaceε of the first houεing 12 define chamber 18. Becauεe housing 12 is designed εo that the εurfaces in closeεt facing relationεhip to each other are acceεεible to bodily fluidε, the housing will allow bodily fluids to pass transversely through it. The term "transverεely" referε to bidirectional flow (shown by the double-headed arrows in Fig. 3), parallel to an axis of the housing, the axis defined by the houεing εurfaceε in closeεt facing relationship to each other. The "depth" of houεing 12 is also defined by the distance between those surfaces of the houεing in closeεt facing relationship to each other. Perforations 20 on first housing 12 thus allow bodily fluidε to flow between the surfaceε that are in closeεt facing relationεhip to each other (i.e. "transversely" through the houεing) . The perforationε 20 of the first housing can be of any shape or dimension, provided that they are smaller than the width (W) of the enclosed membranes 22, to prevent the membrane from escaping out of the first housing.

A plurality of selectively permeable membranes 22 is completely enclosed within chamber 18 of first housing 12. In the embodiment illustrated in Figs. 2 and 3, the membranes 22 are a plurality of tubular, selectively permeable membranes with closed ends 38, the membranes 22 being arranged in a pinwheel configuration within chamber 18. Each membrane of the pinwheel contains cellε 32 for producing a biological agent. Specifically, each individual membrane 22 iε spaced apart from an adjacent membrane by between l-5mm and each individual membrane is arranged radially around a central, membrane-free region 40 of the first houεing 12.

The length of the individual membraneε can range from about 1.0 to about 5.0 cm. The width of each individual membrane 22 can range from about 0.05 cm to about 1.5 cm. Most preferably, the membranes are about 1.0-5.0 cm long by about 0.5 cm wide. The number of membranes will depend upon the size of the first housing 12 and the spacing between individual membraneε. Significantly the number of membraneε in this embodiment, as in the other embodiments, will also be determined by the patient requirement for the biological agent. In the case of diabetes, for example, the number of membranes can be eaεily altered to provide a calibrated amount (e.g. 15, 30, 40 Units) of insulin for delivery.

The individual membranes can be tethered to each other uεing a biocompatible εuture material or attached to an interior surface 15 of the first housing 12. Nevertheless, it is preferred that the individual membranes 22 not be bound together or be affixed to the inεide of the first houεing. Rather, aε illuεtrated in Figε. 2 and 3, small sectionε of inert material 42 (hereinafter called "εpacerε") are constructed to protrude from interior surface 15 of the first housing 12. Spacers 42 physically separate individual membraneε 22 and facilitate circulation of bodily fluidε between membranes. The projection of the εpacerε into the housing can vary so long aε they

-17-

SUBSTIT effectively separate the individual membraneε. Furthermore, the depth of first housing 12 (i.e., the distance between those perforated sides in closeεt facing relationεhip to each other) iε designed so that tranεverse movement of the membranes within chamber 18 is severely constrained. The depth of the houεing iε substantially equal to the width (W) of the membranes. Thus, with thiε size limitation, pluε the εpacerε, the membranes 22 will stay in place without movement.

The size of a typical toroidal first housing 12 ranges from about 3.0 cm in diameter to about 10.0 cm in diameter with a depth of about 1.5 cm. Most preferably, the first houεing shown in Figε. 2 and 3 rangeε from about 3.0 to about 8.0 cm in diameter.

Figs. 4 and 5 illustrate yet another embodiment of the artificial organ. In this embodiment, the first housing 12 iε substantially rectangular in shape. The interior 15 and exterior 17 surfaceε in cloεeεt facing relationεhip to each other contain perforationε 20. Interior surfaces 15 define chamber 18. A plurality of selectively permeable, εubεtantially tubular membraneε 22 are disposed within chamber 18 and are arranged in parallel. The membranes have closed ends 38. Membranes 22 can be arranged to have a length (L) equal to a linear dimension (i.e., width or length) of the first houεing, depending upon which orientation the membraneε are placed. Each of the individual membraneε 22 contain cellε 32 and each membrane iε separated from adjacent membranes by εpacerε 42 projecting from an interior εurface 15 of the firεt houεing. Movement of the individual membranes 22 within chamber 18 iε constrained by the dimensions of the chamber. That iε, the width (W) of any membraneε will be subεtantially identical to the depth of the first housing. A rectangular first houεing 12 of about 8.0 cm x 4.5 cm wide x 0.5 cm in depth iε εuitable for implantation in, for example, the abdominal cavity. The membrane can be about 8.0 cm long x about 0.5 cm wide.

Figure 6 illuεtrates an alternate embodiment with two layers of membranes. Reference numbers are identical to Fig. 5, except where indicated. A first housing 12 has a depth of about 1.0 cm, so that a second layer of membranes 46 is superimposed on top of the first layer of membranes 22. Preferably, spacerε 48 are provided to separate the superi poεed layers of membranes 22 and 46. Spacers 48 preferably traverse the inside of the first housing 12 either along its length, its width, or along both (e.g. in a crisε-cross configuration) . By thus expanding the depth of the first housing 12 to accomodate a plurality of membrane layers, additional biological agent can be released from the artificial organ.

Fig. 7 illuεtrates another embodiment of the artificial organ, showing a significant feature of the present invention; namely that the membrane is constructed to minimize the numbers of its sealed ends and maximize its total surface area. As shown in Fig. 7, a εubstantially disc-like first houεing 12 completely encloses a tubular, selectively permeable membrane 22 whose length iε εubεtantially greater than any linear dimension of the first housing. In the particular embodiment illustrated, the membrane 22 iε a single, coiled tube containing cells 32. It will be readily appreciated that the εurfaceε available for εealing the membrane are limited to the endε 38 of the coiled membrane 22. Thiε iε but one construction that will minimize the ratio: numberε of sealed ends/total εurface area of the membrane.

An interior εurface 15 of firεt houεing 12 defineε chamber 18. Interior surface 15 has a central projection 50. Emanating radially outwardly from the central projection are a serieε of εpacers 42, also protruding from surface 15. Theεe εpacerε 42 separate the coils of the tubular membrane 22 from each other aε it is wound within chamber 18 of housing 12. The first housing has interior 15 and exterior 17 surfaces in closest facing relationship to each other that contain perforations 20.

A preferred first housing is a disk about 8.0 cm in diameter x 0.5 cm in depth. The width (W) of the preferred single, coiled membrane 22 can be εubεtantially equal to the depth of the firεt houεing. The membrane 22 can be of any length; long lengthε are eaεily obtainable by winding the membrane around the central projection 50 in progreεεively larger coilε. It will be underεtood that more than one coiled membrane can be accommodated within the firεt houεing as two or more layers. The number of such membranes (layers) will depend primarily upon the width of the membranes(s) and the depth of the firεt housing.

In another embodiment, the artificial organ includes a pair of concentrically arranged housings that are accesεible to bodily fluidε. The housings can be of any shape (i.e. square, circular, rectangular, and the like). Moεt preferably, the concentrically arranged houεingε are cylindrical. In the embodiment illustrated in Fig. 8, an outer, firεt housing 100 iε a cylinder with a diameter of between about 3 and 4 centimeterε and a height of between about 6 to 10 centimeterε. A second, inner cylindrical housing 105 iε diεpoεed in chamber 106, the chamber 106 defined by the interior εurfaceε 110 of the firεt cylindrical housing 100. The first cylindrical housing 100 has exterior surfaces 115. The second cylindrical housing 105 also haε interior 120 and exterior 125 surfaces. A substantially annular volume 130 is defined between the interior surface.110 of first housing 100 and exterior surface 125 of second housing 105. Diεpoεed within volume 130 iε a εelectively permeable membrane 135.

Moεt preferably, the selectively permeable membrane 135 is wound around the exterior surface 125 of the εecond, inner houεing 105 aε a plurality of coils, the coilε εeparated from each other by a εpacer (alεo in the εhape of a coil) 150 that iε εupported on the exterior εurface 125 of the second, inner housing 105. Cells 155 capable of releasing a biological agent, are dispoεed within the selectively permeable membrane 135.

The exterior and interior surfaces of both the cylinders preferably include perforations 160. The endε 165 of the firεt, outer housing 100 and the endε 170 of the second, inner housing 105, also include perforationε 160 (end perforations are shown only for the interior housing in Fig. 8) . The perforations 160 of the two cylindrical housings 100, 105 allow bodily

-21- SU8STITUTE SHEET(RULE 26) fluidε to paεs transverεely acroεε the device, aε shown by the double-headed arrowε in Fig. 9. Moreover, the perforated endε 165, 170 of the two cylindrical houεingε will allow bodily fluids to paεε through the houεingε in a direction εubεtantially orthogonal to the transverse flow (i.e., parallel to the longitudinal axis of the concentrically arranged houεings) .

Fig. 9 illuεtrateε a partial croεε-εection through line C-C of Fig. 8, with identical reference numberε being uεed, except where indicated. It can be appreciated that the total length of membrane 135 iε the εum of number of coils x the length of each coil, where the length of each coil iε diameter of the inner housing 105. The width (W) of the annular volume 130 (i.e. the distance between the respective εurfaceε 110, 125 of the two cylindrical houεingε) iε preferably εubεtantially equal to the diameter of the selectively permeable membrane 135. This will insure that the selectively permeable membrane is conεtrained within the annular volume, in a manner analogouε to the conεtraintε impoεed by the dimenεionε deεcribed in the previouε embodimentε of thiε invention.

In the embodiment illustrated in Figε. 8 and 9, the second, inner housing iε not fixed to the firεt, outer houεing. That iε, neither exterior εurface 125, nor endε 170 of the εecond, inner houεing 105 are attached to the outer housing 100. It will, however, be understood that one, or both, ends 170 of the second, inner housing 105 can be affixed to the respective endε 165 of the firεt, outer houεing 100 without departing from the scope of the invention.

For example Fig. 10 illuεtrateε an alternate embodiment of Figε. 8 and 9 in which inner housing 105 iε integral with an end 165 of outer houεing 100. Inner houεing 105 lackε a εeparate perforated end εection εo that interior 120 and exterior 125 surfaces of inner housing 105 abut directly against end 165 of the outer houεing 100. All reference numbers are identical to those in Figε. 8 and 9.

Fig. 11 illustrates yet another embodiment of the invention. A substantially disc-shaped firεt housing 12 is shown, with interior and exterior surfaceε 15, 17, respectively, in closest facing relationship to each other containing perforations 20 and being acceεεible to bodily fluids. A tubular, selectively permeable membrane 22 containing cells 32 iε disposed completely within chamber 18, the chamber defined by interior surfaces 15. As εhown in croεs-εection, the membrane 22 defineε a lumen 30 that takes up almost the entire chamber volume. The lumen 30 of membrane 22 can have a volume from about 1% to about 5% smaller than the volume of chamber 18. The sealed edges 38 of membrane 22 are εhown in the croεε-sectional view. It will be appreciated that the ratio of the εealed εurface area of the member to the total εurface area of the membrane is also at a minimum in this particular configuration.

Additional embodiments of the present invention can be readily appreciated by those of ordinary skill in the art. For example, the artificial organ of the preεent invention can include one or more first houεingε εtacked together as a unit, each of the first

-23- SU8STITUTE SHEET(RULE 26) housingε containing a membrane encloεing cellε, aε described herein. Moreover, the membrane can be impregnated or filled with a cellular growth factor or other material to enhance growth of the enclosed surrounding cellε. Growth factorε or other agents such as angiogenic factors, interleukinε, chemotactic factorε, and the like are well known to those of ordinary skill in the art.

Alternately, or in addition, a matrix of collagen or other structural material can be incorporated within the membraneε. Thiε matrix would allow growth of capillarieε which may provide additional nouriεhment for the cellε within the membraneε.

The artificial organε of the present invention can be eaεily fabricated using conventional methods.

Metallic housingε can be fabricated uεing conventional milling procedureε. If plaεtic, houεingε can be made uεing conventional lamination, extruεion and/or molding procedureε. Perforationε can be drilled or incorporated in a mold. Generally, the first housings are fabricated aε open diεcε or boxeε with no top. The depth of the box pluε the top iε about equal to, or only εlightly larger than, the width of the membrane that is to be placed in the first houεing. The membranes are loaded with cell, sealed, and then placed within the first housing. The presence of εpacerε on the interior surfaces of the first housing aidε in the correct poεitioning of the membrane(ε) .

With particular regard to Fig. 2, the toroid is fabricated with a central core, sidewallε, and no top. The depth of the completely aεεembled toroid,

-24-

ΓI IO CT.T αut >t_> < ^{■ ■} ! U τc cuf-TT (RULE 26 including top, is approximately 1-5 mm larger than the width of the membraneε. The interior εurface of the toroid haε εpacerε protruding from it and the membraneε are placed in between the εpacerε. Each membrane haε two εealed endε abutting the outer periphery of the toroid at their one end, and the interior central core of the toroid at their other end. Once the device iε loaded, a top iε then provided and secured by epoxy or screws.

With regard to Fig. 3, the firεt housing is constructed essentially like a cigar box without a top and with a depth slightly greater than the width of the individual membraneε. The membrane is of length equal to a linear dimension of the first housing (i.e., width or length) depending upon the way the membraneε are placed. The interior εurface of the firεt houεing includeε εpacerε to separate the membranes from each other. The firεt housing is closed by attaching a lid with epoxy or screws, as with the previouε embodiment. The εpace between the membraneε is formed by the spacerε in order to provide free flow of bodily fluid around the membrane.

With regard to Fig. 7, the configuration embodied therein iε εubεtantially a circular pill box with no top and a central poεt poεitioned on a interior εurface of the pill box. Emanating from the central poεt are εpacers which separate the coils of the membrane at equal intervals aε the membrane is wound around the central post. The membrane is filled with the appropriate pancreatic isletε and the endε of the membrane are εealed. The membrane iε then be wound around the central post in between the εpacerε. A top of the firεt houεing iε placed on the pill box with epoxy or screwε, aε described above. Alternatively, the membrane can be εealed at one end, wound around the central poεt, and then filled and εealed while it iε in the open pill box. Then, the top iε placed on the open pill box.

The concentrically arranged cylinderε of Figureε 8-10 iε aεεembled in a similar manner. The membrane is filled with the appropriate pancreatic islets and the ends of the membrane are sealed. The membrane iε then be wound around the inner houεing in between the εpacerε. An open end of the firεt, outer housing iε sealed by placing a perforated end section on the outer housing with epoxy or screwε, aε deεcribed above. Alternatively, the membrane can be sealed at one end, wound around the inner houεing, and then filled and sealed while it is in the open outer houεing. Then, the end is placed on the outer housing.

The invention also pertains to artificial organ kitε uεed for eaεe of εurgical operationε. The kit containε a membrane filled with a biologically active cell (i.e. pancreatic iεlet cells). The membrane iε contained within the firεt houεing, aε deεcribed herein and completely assembled, either in the operating room immediately pre-operation, or asεembled in a laboratory and εhipped to the operating room in a εterile container. Sterilization uεing, for example, ethylene oxide, and methods of shipping and packing medical devices to maintain sterility are well-known to those workers of ordinary skill in the art.

The implantable artificial organ of the preεent invention can be placed in any body cavity. The preferred location within a preferred εubject (i.e. a mammal such aε a human) iε the peritoneal cavity. The moεt preferred location in human subjects is in the lower abdominal cavity; in the area called the "anatomic pouch of Douglas". The pouch of Douglas iε the deepeεt, moεt dependent portion of the peritoneal cavity in a patient that iε εtanding erect. The artificial organ of the invention iε placed in the "pouch of Douglaε" and allowed to be paεεoively bathed with bodily fluid in the abdominal cavity. About 500 cc's of saline solution is added to the pouch area so that the artificial organ housing iε well bathed initially.

The artificial organ is placed in a body cavity of a subject by a lower abdominal mid-line incision performed under local anestheεia. This involves, at best, day surgery, i.e. the patient comes in the morning, haε the placement done, and iε allowed to go home on the same day. The length of the lower abdominal mid-line incision iε determined by the maximum diameter or length of the firεt housing. A firεt housing can be made εmall enough εo that it could be inserted by laparoscopic techniqueε. Thiε can be done if the firεt housing iε constructed as a rectangle with a measurement of perhaps 2 or 3 cm by 6 or 8 cm. Once implanted, the functioning of the implantable artificial organ can be easily tested by monitoring bodily fluids of the εubject for the particular beneficial agent expected to be produced by the cell. Increases in levels over "background" (i.e. preimplantation) indicate the implantable organ is functioning. Without question, the placement of the artificial organ of the invention in the human body must have the possibility of being completely removed, retrieved, and/or recharged and reimplanted utilizing relatively simple methods. If one were to have membraneε by themεelveε in the abdominal cavity in multiple numberε, i.e. 50, 100 or 200 membraneε, the chanceε of retrieving them completely and easily would be extremely difficult. Membranes, encloεed within, and protected by, a firεt houεing makes retrievability of the artificial organ very easy. The housingε would be removed and poεεibly re-implanted with fresh cells the same way they were placed, i.e. through a lower mid-line abdominal incision performed under local anesthesia. Placement or removal of the artificial organ in the pouch of Douglas can be a εimple operation of very εhort duration.

The artificial organε are ideal for placement in the abdominal pouch of Douglaε in that their configuration and their weight maintain the artificial organ houεing in the pouch area. The artificial organ can alεo be anchored in the pouch of Douglaε by a εingle suture or two to the posterior parietal peritoneum. Thus, eaεe of placement, εecurity of placement, and anchoring of placement in thiε area are advantageε inherent in the preεent invention. Since the artificial organ iε preferably located in that portion the of the body where peritoneal fluid collect, becauεe of dependency (i.e. being the loweεt portion), the device iε continually bathed in bodily fluidε.

The artificial organ of the invention alεo protectε the membraneε from being broken while in the body and therefore protectε their integrity from a possible immune rejection from the body's immunological reactivity. Moεt prior art diffuεion membrane configurationε are such that the membrane iε eaεily breakable because of torque or twisting impoεed on the membraneε when they move around freely in the abdominal cavity. Since the membranes of the preεent artificial organ are prevented from movement and protected from outside presεureε, the likelihood of them breaking is esεentially zero.

The use of certain configurations of the membraneε permitε reduction or minimization of the number of ends that have to be sealed to contain the cellε. For instance, in the embodiment of Fig. 4, only two endε need to be εealed, irreεpective of the length of the membrane. Thuε, with a membrane length of 80 cm, only two endε would have to be εealed; if 40 membraneε of 2 cm each were uεed (80 cm total length), one would have to have 80 εuch sealε. The advantage of juεt having two endε to εeal iε manifest.

The invention will now be further illustrated by the following non-limiting example.

EXAMPLE I Isolation of islets from pancreatic tiεεue

Islets of Langerhans are obtained from the pancreas of donor animals (e.g. dog, cattle, pig) . Isletε of Langerhans are isolated and purified by modifications of published procedures. See, Gotoh et al.. Transplantation, 40(4) :437-438 (1985). Briefly, an intact pancreas is infused by way of the pancreatic duct with a suspension of collagenase which digeεtε connective tiεεue and diεruptε the integrity of the gland. The gland iε further diεεociated by εhaking it until cell fragmentε become εmall, centrifuging the fragmentε, and paεεing the pelleted fragmentε through a meεh filter (opening 860 microns, Bellco, Vineland, NJ) to remove the large undigeεted tiεεues, which usually consiεtε of meεenteric lymph nodeε and large veεεel fragmentε. Thiε diεεociation procedure releases isletε from the tiεεue that surrounds them. Isletε are then εeparated from non-iεlet cell by centrif gation (800g for about 10 minuteε) on a diεcontinuouε gradient of Ficoll (Pharmacia Fine Chemicalε, Inc.) (23% w/v; 20.5% w/v; and 11% w/v) , which utilizeε the difference in denεity of cell typeε to permit iεletε to be poεitioned at the interface of the 11% and 20.5% Ficoll layerε. Iεletε are collected, waεhed and plated into culture plateε until uεed.

EQUIVALENTS

This invention haε been particularly shown and described with references to preferred embodiments thereof. It will be understood by those skilled in the art that various changes in form and details may be made therein without departing from the spirit and scope of the invention as defined by the appended claims.

Claims

1. An artificial organ for implantation into a subject, compriεing: a firεt housing having at least one interior εurface and at least one exterior surface, εaid at leaεt one interior εurface defining a chamber, at leaεt a portion of εaid houεing acceεεible to bodily fluids of said subject; a membrane disposed within said chamber, at least a portion of said membrane selectively permeable to bodily fluids of εaid εubject; and one or more cellε diεpoεed within εaid selectively permeable membrane for producing a biological agent.

2. The artificial organ of claim 1, wherein said first housing includes a plurality of interconnected surfaceε, two of said interconnected surfaceε in cloεeεt facing relationεhip to each other being acceεεible to bodily fluidε.

3. The artificial organ of claim 2, wherein εaid two interconnected surfaces are perforated so that bodily fluids pasε transversely through said first housing and into said membrane.

4. The artificial organ of claim 2, wherein said of selectively permeable membranes.

5. The artificial organ of claim 4, wherein said plurality of selectively permeable membranes is arranged in a pinwheel pattern.

6. The artificial organ of claims 2 or 4, wherein said membrane comprises a plurality of spaced-apart selectively permeable membranes arranged in parallel.

7. The artificial organ of claim 1, wherein said first housing and selectively permeable membrane define therebetween a volume that iε acceεεible to bodily fluidε.

8. The artificial organ of claim 1, wherein εaid εelectively permeable membrane comprises a coiled tube.

9. The artificial organ of claim 1, further comprising a cellular growth factor diεpoεed within εaid selectively permeable membrane.

10. The artificial organ of claim 1, wherein said cellε compriεe islet of Langerhans cellε.

11. The artificial organ of claim 3, wherein εaid two εurfaceε include perforationε with εubεtantially circular croεε-εection.

12. The artificial organ of claim 3, wherein εaid two surfaces include a meshwork configuration.

13. An artificial organ for implantation into a subject comprising a first housing, having an interior surface and an exterior surface, said interior surface defining a chamber, said housing accessible to bodily fluids and in fluid communication with said exterior surface; a selectively permeable membrane disposed within said chamber, εaid membrane containing one or more cellε capable of producing a biological agent; εaid one or more cells in in fluid communication with εaid chamber.

14. The artificial organ of claim 13, wherein εaid firεt housing is perforated to provide for flow of bodily fluids transversely through εaid chamber.

15. The artificial organ of claim 13, wherein said εelectively permeable membrane haε a length substantially greater than any linear dimension of said firεt houεing.

16. The artificial organ of claim 13, further compriεing a second housing disposed within said first housing, said εecond houεing having an interior εurface and an exterior surface, said interior surface of εaid firεt housing and said exterior surface of said second houεing defining therebetween a volume, εaid εelectively permeable membrane disposed within said volume.

17. The artificial organ of claim 16, wherein said second housing is accessible to bodily fluids.

18. The artificial organ of claim 17, wherein said selectively permeable membrane is supported on the exterior surface of said second housing.

19. The artificial organ of claim 18, wherein said selectively permeable membrane is dispoεed as a tube coiled around the exterior surface of εaid second housing.

20. The artificial organ of claim 13, wherein, said selectively permeable membrane iε a coiled tube.

21. The artificial organ of claim 13, wherein said biological agent is a hormone.

22. The artificial organ of claim 13, wherein said selectively permeable membrane has a volume εubεtantially equal to a volume of εaid chamber.

23. An implantable artificial organ compriεing, a pair of concentrically arranged houεingε, a εubstantially annular volume defined between said concentrically arranged housing, at least one of εaid houεingε acceεεible to bodily fluids; a selectively permeable membrane dispoεed within εaid annular volume; cells disposed within said selectively permeable membrane for producing a biological agent.

24. The implantable artificial organ of claim 23, wherein each of said housingε iε a cylinder.

25. The implantable artificial organ of claim 24, wherein each cylinder of said pair of cylinders is perforated to provide for access to bodily fluids.

26. The implantable artificial organ of claim 25, wherein each cylinder of said pair of cylinders include endε that are perforated.

27. A method of delivering a beneficial agent to a εubject, compriεing the^' steps of: implanting into a subject an artificial organ including: a firεt houεing, at leaεt a portion of said housing accessible to bodily fluids of εaid εubject; a membrane diεposed within said first housing, at leaεt a portion of εaid membrane εelectively permeable to bodily fluidε of εaid εubject; and cellε disposed within said membrane for producing a biological agent; and allowing said biological agent made by εaid cell to be released into said bodily fluids of said subject.

28. The method of claim 27, further comprising monitoring said bodily fluids of said subject for production of said biological agent.

29. The method of claim 27, wherein the artificial organ is implanted into a body cavity of said εubject.

30. The method of claim 29, wherein εaid body cavity compriεes the pouch of Douglas.